



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/973,576	04/02/1998	BERNARD Malfroy-Camine	15390-00013U	7067

7590

03/21/2002

EUGENIA GARRETT-WACKOWSKI
TOWNSEND & TOWNSEND & CREW
TWO EMBARCADERO CENTER
8TH FLOOR
SAN FRANCISCO, CA 941113834

EXAMINER

SCHWADRON, RONALD B

ART UNIT

PAPER NUMBER

1644

DATE MAILED: 03/21/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
08/973,576

Applicant(s)
Malfroy-Camine

Examiner
Ron Schwadron

Art Unit
1644



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on Jan 7, 2002
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-22 and 24 is/are pending in the application.
- 4a) Of the above, claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5, 7-10, 12-22, and 24 is/are rejected.
- 7) ☒ Claim(s) 6 and 11 is/are objected to.
- 8) ☐ Claims _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
- a) ☐ All b) ☐ Some* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- *See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) ☐ Notice of References Cited (PTO-892)
- 16) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____
- 18) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 19) ☐ Notice of Informal Patent Application (PTO-152)
- 20) ☐ Other:

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/7/2002 has been entered.

2. Claims 1-22,24 are under consideration.

3. The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); and *In re Goodman*, 29 USPQ2d 2010 (Fed. Cir. 1993).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(b) and © may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.78(d).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

4. Claims 14-22 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1,2,4-12,24,29-33 of copending application Serial No. 08/483944 for the reasons elaborated in the previous Office Action.

Applicant has indicated that this issue will be addressed at a later date.

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 1-5,7-10,12-22,24 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the claimed method or product using the lipid glycyldioctadecylamide, does not reasonably provide enablement for the claimed inventions. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

According to applicants comments in the interviews of February 17 and 22, 2000, based on the Horan et al. reference it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane. The prior art rejection has been dropped based on this interpretation of the Horan et al. reference. During the interview, BPS Schwartz inquired that in lieu of this unpredictability, how many examples of lipidized proteins were disclosed in the specification. Applicant indicated that there were numerous examples in the specification. However, all of the examples disclosed in the specification use a single type of lipid to create lipidized proteins (eg. glycyldioctadecylamide). Thus, while applicant has argued that Horan et al. disclose that it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane, there is only disclosure in the specification of use of a single size of lipid in the creation of lipidized proteins. The claims encompass lipidized proteins containing a lipid with a hydrocarbon tail of greater than 12 carbons. The claims also state that the lipidized protein localizes intracellularly. Therefore, the enablement provided in the specification is not commensurate with the scope of the claimed inventions because Horan et al. disclose that it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane, there is only disclosure in the specification of use of a single size of lipid in the creation of lipidized proteins and the claims encompass lipidized proteins containing a lipid with a hydrocarbon tail of greater than 12 carbons.

Regarding applicants comments, the MPEP section 2164.03 (Rev. 1, Feb. 2000)

states:

However, in applications directed to inventions in arts where the results are unpredictable, the disclosure of a single species usually does not provide an adequate basis to support generic claims. In re Soll, 97 F.2d 623, 624, 38 USPQ 189, 191 (CCPA 1938). In cases involving unpredictable factors, such as most chemical reactions and physiological activity, more may be required. In re Fisher, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970) (contrasting mechanical and electrical elements with chemical reactions and physiological activity). See also In re Wright, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993); In re Vaeck, 947 F.2d 488, 496, 20 USPQ2d 1438, 1445 (Fed. Cir. 1991). This is because it is not obvious from the disclosure of one species, what other species will work.

Applicant has already previously argued that it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane. The instant specification only provides examples using a single type of lipid of a single size. According to applicants comments in the interviews of February 17 and 22, 2000, based on the Horan et al. reference it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane. The prior art rejection has been dropped based on this interpretation of the Horan et al. reference. During the interview, BPS Schwartz inquired that in lieu of this unpredictability, how many examples of lipidized proteins were disclosed in the specification. Applicant indicated that there were numerous examples in the specification. However, all of the examples disclosed in the specification use a single type of lipid to create lipidized proteins (eg. glycyldioctadecylamide). Thus, while applicant has argued that Horan et al. disclose that it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane, there is only disclosure in the specification of use of a single size of lipid in the creation of lipidized proteins. The claims encompass lipidized proteins containing a lipid with a hydrocarbon tail of greater than 12 carbons. The claims also state that the lipidized protein localizes intracellularly. Therefore, the enablement provided in the specification is not commensurate with the scope of the claimed inventions because Horan et al. disclose that

it is unpredictable whether lipidized proteins that contain an added hydrocarbon tail of greater than 12 carbons will localize intracellularly or localize in the cell membrane, there is only disclosure in the specification of use of a single size of lipid in the creation of lipidized proteins and the claims encompass lipidized proteins containing a lipid with a hydrocarbon tail of greater than 12 carbons.

Applicants comments are drawn to the Malfroy-Camine declaration filed 1/7/2002. However, said declaration has been received in incomplete form. According to paragraph 5 of said declaration, an Exhibit A with the Malfroy-Camine curriculum vitae was to be submitted as part of said declaration. Exhibit A has not been received. The Malfroy-Camine declaration and applicants comments regarding said declaration will be fully considered upon receipt of this missing section of the Malfroy-Camine declaration.

7. Claims 6 and 11 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

8. No claim is allowed.

9. All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from

the mailing date of this final action.

9. Papers related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 1600 at (703) 308-4242.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Monday through Thursday from 7:30 to 6:00. A message may be left on the examiners voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ms. Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1600 lwo



Ron Schwadron, Ph.D.
Primary Examiner
Art Unit 1644